奈西立肽联合沙库巴曲缬沙坦治疗心力衰竭的临床效果及安全性分析  

Analysis on the Clinical Effect and Safety of Nesiritide Combined with Sacubitril/Valsartan in the Treatment of Heart Failure

作　　者：董艳彩 刘继烈[2] DONG Yancai;LIU Jilie(Department of Cardiology,the Second Affiliated Hospital of Luohe Medical College,Luohe 462007,China;Department of Cardiology,Luohe Central Hospital,Luohe 462007,China)

机构地区：[1]漯河医专二附院心内科,河南漯河462007 [2]漯河市中心医院心内科,河南漯河462007

出　　处：《临床医学工程》2022年第6期791-792,共2页Clinical Medicine & Engineering

摘　　要：目的 分析奈西立肽联合沙库巴曲缬沙坦治疗心力衰竭的效果与安全性。方法 112例心力衰竭患者随机分为两组,参照组给予奈西立肽治疗,联合组给予奈西立肽联合沙库巴曲缬沙坦治疗,比较两组的治疗效果、不良反应以及心功能指标。结果 联合组的治疗总有效率为96.43%,高于参照组的82.14%(P<0.05)。治疗后,联合组的LVEDD、 LVESD均低于参照组,LVEF高于参照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 奈西立肽联合沙库巴曲缬沙坦治疗心力衰竭的效果显著,有助于改善患者的心功能,且不会明显增加不良反应。Objective To analyze the effect and safety of nesiritide combined with sacubitril/valsartan in the treatment of heart failure. Methods 112 patients with heart failure were randomly divided into two groups. The reference group was treated with nesiritide, while the combined group was treated with nesiritide combined with sacubitril/valsartan. The curative effects, adverse reactions and cardiac function indicators of the two groups were compared. Results The total effective rate of treatment in the combined group was 96.43%, higher than 82.14% in the reference group(P <0.05). After treatment, the LVEDD and LVESD in the combined group were lower than those in the reference group, and the LVEF was higher than that in the reference group(P <0.05). No significant difference was found in the incidence of adverse reactions between the two groups(P >0.05). Conclusions Nesiritide combined with sacubitril/valsartan in the treatment of heart failure has significant effect, which helps to improve the cardiac function of patients without significantly increasing adverse reactions.

关 键 词：心力衰竭 奈西立肽 沙库巴曲缬沙坦 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]